| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762488476P | 2017-04-21 | 2017-04-21 | |
| US201762592542P | 2017-11-30 | 2017-11-30 | |
| US201862658454P | 2018-04-16 | 2018-04-16 | |
| PCT/US2018/028532WO2018195397A2 (en) | 2017-04-21 | 2018-04-20 | Indole ahr inhibitors and uses thereof |
| Publication Number | Publication Date |
|---|---|
| SG11201909710XAtrue SG11201909710XA (en) | 2019-11-28 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909710XSG11201909710XA (en) | 2017-04-21 | 2018-04-20 | Indole ahr inhibitors and uses thereof |
| Country | Link |
|---|---|
| US (5) | US10570138B2 (en) |
| EP (1) | EP3612030A4 (en) |
| JP (2) | JP7232244B2 (en) |
| KR (1) | KR102668371B1 (en) |
| CN (1) | CN110831600B (en) |
| AU (1) | AU2018256459B2 (en) |
| CA (1) | CA3059939A1 (en) |
| CL (1) | CL2019003015A1 (en) |
| CO (1) | CO2019011584A2 (en) |
| IL (1) | IL270025B2 (en) |
| MX (1) | MX2019012431A (en) |
| SG (1) | SG11201909710XA (en) |
| TW (1) | TWI778050B (en) |
| WO (1) | WO2018195397A2 (en) |
| ZA (1) | ZA201906822B (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20190282A (en) | 2016-12-16 | 2019-08-21 | Janssen Pharmaceutica Nv | Small molecule inhibitors of the jak family of kinases |
| JOP20190144A1 (en) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | Imidazopyrrolopyridine as inhibitors of the jak family of kinases |
| TW201841916A (en)* | 2017-04-12 | 2018-12-01 | 美商麥珍塔治療學股份有限公司 | Aromatic hydrocarbon receptor antagonists and uses thereof |
| SG11201909710XA (en) | 2017-04-21 | 2019-11-28 | Kyn Therapeutics | Indole ahr inhibitors and uses thereof |
| FR3066761B1 (en)* | 2017-05-23 | 2020-10-30 | Centre Nat Rech Scient | NEW IONIC CHANNEL INHIBITORS |
| KR20200051646A (en) | 2017-08-17 | 2020-05-13 | 이케나 온콜로지, 인코포레이티드 | AHR inhibitors and uses thereof |
| WO2019156989A1 (en)* | 2018-02-06 | 2019-08-15 | Ideaya Biosciences, Inc. | COMPOUNDS AND METHODS FOR THE MODULATION OF AhR |
| FI3749669T6 (en) | 2018-02-06 | 2024-11-13 | Ideaya Biosciences Inc | Ahr modulators |
| TW202016110A (en) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Small molecule inhibitors of the JAK kinase family |
| US11932657B2 (en)* | 2018-09-07 | 2024-03-19 | Otsuka Pharmaceutical Co., Ltd. | Heterocyclic compound |
| SG11202103796TA (en)* | 2018-10-16 | 2021-05-28 | Ikena Oncology Inc | Indole ahr inhibitors and uses thereof |
| WO2020081840A1 (en)* | 2018-10-17 | 2020-04-23 | Magenta Therapeutics Inc. | Methods of treating cancer with aryl hydrocarbon receptor antagonists |
| EA202191507A1 (en)* | 2018-11-30 | 2021-08-20 | Селулэрити Инк. | AROMATIC COMPOUNDS FOR USE TO ACTIVATE HEALTH STEM CELLS AND PROCESS CELLS |
| EP3887508A1 (en)* | 2018-11-30 | 2021-10-06 | Celularity Inc. | Expansion of natural killer cells and ilc3 cells with novel aromatic compounds |
| CN109813913B (en)* | 2019-01-31 | 2021-11-09 | 中国医学科学院肿瘤医院 | Use of aromatic hydrocarbon receptor (AhR) for predicting immunotherapy effect |
| CA3128521A1 (en)* | 2019-02-27 | 2020-09-03 | Millennium Pharmaceuticals, Inc. | Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors |
| EP4003337A4 (en)* | 2019-07-30 | 2023-06-28 | Oregon State University | Aryl hydrocarbon receptor activators |
| KR20220119537A (en)* | 2019-11-22 | 2022-08-29 | 센다 바이오사이언시즈, 인크. | Pyridopyrimidinone derivatives as AHR antagonists |
| ES3028099T3 (en) | 2019-11-26 | 2025-06-18 | Ikena Oncology Inc | Polymorphic carbazole derivatives and uses thereof |
| EP4065586A1 (en)* | 2019-11-26 | 2022-10-05 | F. Hoffmann-La Roche AG | 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease |
| MX2022006312A (en)* | 2019-11-26 | 2022-06-22 | Ikena Oncology Inc | Ahr inhibitors and uses thereof. |
| TW202146416A (en) | 2019-12-11 | 2021-12-16 | 德商拜耳廠股份有限公司 | Pyrazolotriazines |
| KR20220125323A (en) | 2020-01-10 | 2022-09-14 | 이케나 온콜로지, 인코포레이티드 | AHR inhibitors and uses thereof |
| KR20220153595A (en) | 2020-02-26 | 2022-11-18 | 재규어 테라퓨틱스 피티이 리미티드 | Pyridopyrimidine derivatives useful for modulating AhR signaling |
| KR20230005844A (en)* | 2020-03-27 | 2023-01-10 | 동아에스티 주식회사 | Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators |
| US20240350492A1 (en) | 2020-07-10 | 2024-10-24 | Ting Therapeutics Llc | Methods for the Prevention and Treatment of Hearing Loss |
| WO2022029063A1 (en)* | 2020-08-04 | 2022-02-10 | Bayer Aktiengesellschaft | Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines |
| CN114369097B (en)* | 2020-10-15 | 2023-07-14 | 山东轩竹医药科技有限公司 | Heteroaromatic AhR inhibitors |
| EP4236960A1 (en) | 2020-10-28 | 2023-09-06 | Ikena Oncology, Inc. | Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine |
| CN114644627B (en)* | 2020-12-18 | 2024-06-11 | 山东轩竹医药科技有限公司 | AhR inhibitors and uses thereof |
| CN112656789A (en)* | 2020-12-31 | 2021-04-16 | 中国科学院生态环境研究中心 | Application of FICZ in inhibiting tumor cell migration |
| CN114805361B (en)* | 2021-01-17 | 2024-02-20 | 上海凌达生物医药有限公司 | Amino substituted aromatic heterocyclic pyrazole compound, preparation method and application |
| CA3213134A1 (en) | 2021-03-11 | 2022-09-15 | Janssen Pharmaceutica Nv | Lorpucitinib for use in the treatment of jak mediated disorders |
| WO2023020512A1 (en)* | 2021-08-16 | 2023-02-23 | 成都奥睿药业有限公司 | Substituted pyridine analogue, preparation method therefor, and use thereof as ahr modulator |
| WO2023033742A1 (en)* | 2021-09-02 | 2023-03-09 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| WO2023033741A1 (en)* | 2021-09-02 | 2023-03-09 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| EP4396191A1 (en)* | 2021-09-02 | 2024-07-10 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| CN115093400B (en)* | 2021-09-18 | 2023-09-05 | 北京华森英诺生物科技有限公司 | AhR inhibitor, application and preparation method thereof |
| WO2023060227A1 (en) | 2021-10-07 | 2023-04-13 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CN115925684B (en)* | 2021-12-03 | 2025-02-28 | 徐诺药业(南京)有限公司 | A pyrimidine derivative and its preparation method and application |
| JP2025502240A (en) | 2022-01-11 | 2025-01-24 | ドイッチェス・クレープスフォルシュングスツェントルム | Bicyclic triazine derivatives for the treatment of cancer - Patents.com |
| CN117624168A (en)* | 2022-08-19 | 2024-03-01 | 德明药泰生物技术(深圳)有限公司 | Fused ring heterocyclic compounds and their preparation methods and applications |
| CN115850329A (en)* | 2022-09-16 | 2023-03-28 | 东莞市均成高新材料有限公司 | Cyclic teraryl phosphines, their preparation and use |
| KR20250073623A (en) | 2022-10-03 | 2025-05-27 | 재규어 테라퓨틱스 피티이 리미티드 | Compounds useful for modulating AhR signaling |
| CN115804776A (en)* | 2022-12-16 | 2023-03-17 | 国纳之星(上海)纳米科技发展有限公司 | Application of aromatic hydrocarbon receptor inhibitor and 5-fluorouracil in combination in tumor treatment and inhibition drugs |
| CN116482278B (en)* | 2023-05-06 | 2024-02-09 | 广州清瑞生物科技有限责任公司 | Preparation method of reference substance for detecting acyclovir |
| TW202510855A (en)* | 2023-08-18 | 2025-03-16 | 美商英塞特公司 | Bicyclic heterocycles as mrgprx2 antagonists |
| EP4512806A1 (en) | 2023-08-25 | 2025-02-26 | Mablink Bioscience | Molecular glue degraders and uses thereof |
| EP4512427A1 (en) | 2023-08-25 | 2025-02-26 | Mablink Bioscience | Antibody-drug conjugates based on molecular glue degraders and uses thereof |
| CN117229284B (en)* | 2023-11-10 | 2024-02-06 | 上海泽德曼医药科技有限公司 | Tricyclic fused heterocyclic compound, preparation method and application thereof in medicine |
| WO2025114771A1 (en) | 2023-11-29 | 2025-06-05 | Latvian Institute Of Organic Synthesis | A new class of aryl hydrocarbon receptor antagonists and their optimisation |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721356A (en) | 1989-09-15 | 1998-02-24 | Gensia, Inc. | Orally active adenosine kinase inhibitors |
| EA006626B1 (en)* | 1996-07-24 | 2006-02-24 | Дюпон Фармасьютикалз Компани | Azolo pyrimidines, pharmaceutical composition and method for treatment |
| US5962473A (en) | 1996-08-16 | 1999-10-05 | Eli Lilly And Company | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| SK8192003A3 (en) | 2000-12-19 | 2003-10-07 | Merck Patent Gmbh | Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives |
| US20040235877A1 (en)* | 2001-09-14 | 2004-11-25 | Natsuki Ishizuka | Novel use of tricyclic compound |
| JP2006501260A (en)* | 2002-09-04 | 2006-01-12 | シェーリング コーポレイション | Pyrazolopyrimidines as cyclin-dependent kinase inhibitors |
| KR20050052500A (en)* | 2002-09-19 | 2005-06-02 | 쉐링 코포레이션 | Imidazopyridines as cyclin dependent kinase inhibitors |
| AU2004230928B2 (en) | 2003-04-09 | 2010-12-02 | Exelixis, Inc. | Tie-2 modulators and methods of use |
| AR047969A1 (en) | 2004-02-25 | 2006-03-15 | Schering Corp | PIRAZOLOTRIAZINAS AS QUINASA INHIBITORS |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| AU2005323311A1 (en) | 2004-11-23 | 2006-07-13 | Venkateswara Rao Batchu | Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them |
| PT2343320T (en) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anti-gitr antibodies and uses thereof |
| EP1879573B1 (en) | 2005-05-10 | 2012-12-19 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
| CA3201163A1 (en) | 2005-07-01 | 2007-01-11 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| US20070078136A1 (en)* | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| CA2634198C (en) | 2005-12-20 | 2014-06-03 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| ES2444574T3 (en) | 2006-09-19 | 2014-02-25 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indolamine 2,3-dioxygenase |
| CL2007002650A1 (en) | 2006-09-19 | 2008-02-08 | Incyte Corp | COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS. |
| AU2007316417B2 (en)* | 2006-11-06 | 2013-08-22 | Tolero Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| WO2009009116A2 (en) | 2007-07-12 | 2009-01-15 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| CN101932325B (en) | 2007-11-30 | 2014-05-28 | 新联基因公司 | Ido inhibitors |
| EP2229390B1 (en)* | 2007-12-14 | 2014-04-09 | F. Hoffmann-La Roche AG | Novel imidazoý1,2-a¨pyridine and imidazoý1,2-b¨pyridazine derivatives |
| KR20110013421A (en) | 2008-05-29 | 2011-02-09 | 생-고뱅 생트레 드 레체르체 에 데투드 유로삐엔 | Aluminum titanate-containing porous structure |
| AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
| PE20100362A1 (en) | 2008-10-30 | 2010-05-27 | Irm Llc | PURINE DERIVATIVES THAT EXPAND HEMATOPOYETIC STEM CELLS |
| PT4209510T (en) | 2008-12-09 | 2024-04-02 | Hoffmann La Roche | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| ES2788869T3 (en) | 2009-09-03 | 2020-10-23 | Merck Sharp & Dohme | Anti-GITR antibodies |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| JP5802676B2 (en) | 2009-12-04 | 2015-10-28 | センワ バイオサイエンシズ インコーポレイテッド | Pyrazolopyrimidines and related heterocyclic compounds as CK2 inhibitors |
| RU2565541C2 (en) | 2009-12-10 | 2015-10-20 | Ф.Хоффманн-Ля Рош Аг | Antibodies primarily binding to extracellular domain 4 of human csf-1r, and using them |
| BR122016002916B8 (en) | 2010-03-04 | 2021-05-25 | Macrogenics Inc | diabody, nucleic acid molecule, pharmaceutical composition and uses of diabody |
| KR101647871B1 (en) | 2010-03-05 | 2016-08-11 | 에프. 호프만-라 로슈 아게 | Antibodies against human csf-1r and uses thereof |
| BR112012020372A8 (en) | 2010-03-05 | 2018-01-02 | Hoffmann La Roche | human csf-1r binding antibody, pharmaceutical composition, nucleic acid, expression vectors, host cell and method for producing a recombinant antibody |
| SG10201911345WA (en) | 2010-05-04 | 2020-01-30 | Five Prime Therapeutics Inc | Antibodies that bind csf1r |
| PE20131465A1 (en) | 2010-09-09 | 2014-01-04 | Pfizer | UNION MOLECULES A 4-1 BB |
| US8957077B2 (en)* | 2010-09-30 | 2015-02-17 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine PDE 10 inhibitors |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| NO2694640T3 (en) | 2011-04-15 | 2018-03-17 | ||
| KR101970025B1 (en) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Antibodies and other molecules that bind b7-h1 and pd-1 |
| SG194549A1 (en) | 2011-04-21 | 2013-12-30 | Origenis Gmbh | Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors |
| AU2012344260B2 (en) | 2011-11-28 | 2017-09-07 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| AU2012347534B2 (en)* | 2011-12-08 | 2018-01-25 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells |
| US10023643B2 (en) | 2011-12-15 | 2018-07-17 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
| EP2812355A4 (en) | 2012-02-06 | 2016-03-02 | Hoffmann La Roche | COMPOSITIONS AND METHODS OF USING CSF1R INHIBITORS |
| AR090263A1 (en) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME |
| AR090650A1 (en) | 2012-04-12 | 2014-11-26 | Alcon Res Ltd | TREATMENT FOR INFLAMMATORY RESPONSES INDUCED BY EYE MICROBES |
| HK1208233A1 (en) | 2012-05-11 | 2016-02-26 | 戊瑞治疗有限公司 | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| UY34887A (en) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
| US20140079699A1 (en) | 2012-08-31 | 2014-03-20 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| WO2014060112A1 (en)* | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Pyrazolo[4,3-d]pyrimidines as kinase inhibitors |
| WO2014138485A1 (en)* | 2013-03-08 | 2014-09-12 | Irm Llc | Ex vivo production of platelets from hematopoietic stem cells and the product thereof |
| WO2017004405A1 (en) | 2015-07-01 | 2017-01-05 | Northwestern University | Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity |
| US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| TW201841916A (en) | 2017-04-12 | 2018-12-01 | 美商麥珍塔治療學股份有限公司 | Aromatic hydrocarbon receptor antagonists and uses thereof |
| SG11201909710XA (en) | 2017-04-21 | 2019-11-28 | Kyn Therapeutics | Indole ahr inhibitors and uses thereof |
| SG11202103796TA (en) | 2018-10-16 | 2021-05-28 | Ikena Oncology Inc | Indole ahr inhibitors and uses thereof |
| ES3028099T3 (en) | 2019-11-26 | 2025-06-18 | Ikena Oncology Inc | Polymorphic carbazole derivatives and uses thereof |
| MX2022006312A (en) | 2019-11-26 | 2022-06-22 | Ikena Oncology Inc | Ahr inhibitors and uses thereof. |
| KR20220125323A (en) | 2020-01-10 | 2022-09-14 | 이케나 온콜로지, 인코포레이티드 | AHR inhibitors and uses thereof |
| EP4236960A1 (en) | 2020-10-28 | 2023-09-06 | Ikena Oncology, Inc. | Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine |
| Publication number | Publication date |
|---|---|
| US10570138B2 (en) | 2020-02-25 |
| IL270025A (en) | 2019-12-31 |
| EP3612030A4 (en) | 2021-04-28 |
| EP3612030A2 (en) | 2020-02-26 |
| CN110831600A (en) | 2020-02-21 |
| US20230028336A1 (en) | 2023-01-26 |
| US20200331917A1 (en) | 2020-10-22 |
| US20250122205A1 (en) | 2025-04-17 |
| BR112019021992A2 (en) | 2020-06-09 |
| JP2020517734A (en) | 2020-06-18 |
| WO2018195397A2 (en) | 2018-10-25 |
| IL270025B1 (en) | 2023-01-01 |
| JP2022116319A (en) | 2022-08-09 |
| AU2018256459A1 (en) | 2019-11-07 |
| CO2019011584A2 (en) | 2020-02-18 |
| ZA201906822B (en) | 2024-06-26 |
| JP7232244B2 (en) | 2023-03-08 |
| WO2018195397A3 (en) | 2018-12-13 |
| AU2018256459B2 (en) | 2023-12-07 |
| US10689388B1 (en) | 2020-06-23 |
| CA3059939A1 (en) | 2018-10-25 |
| CN110831600B (en) | 2023-10-17 |
| US11358969B2 (en) | 2022-06-14 |
| MX2019012431A (en) | 2020-08-03 |
| KR20190141722A (en) | 2019-12-24 |
| TW201841917A (en) | 2018-12-01 |
| KR102668371B1 (en) | 2024-05-28 |
| US12077542B2 (en) | 2024-09-03 |
| IL270025B2 (en) | 2023-05-01 |
| US20180327411A1 (en) | 2018-11-15 |
| CL2019003015A1 (en) | 2020-03-27 |
| TWI778050B (en) | 2022-09-21 |
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909710XA (en) | Indole ahr inhibitors and uses thereof | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201808799SA (en) | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201808682XA (en) | Silicone atoms containing ivacaftor analogues | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201805449PA (en) | Methods of making chimeric antigen receptor -expressing cells | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201811643TA (en) | Compounds and methods for modulating rna function | |
| SG11201808751SA (en) | T cell receptors | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201901251SA (en) | Aminopyrimidines as alk inhibitors | |
| SG11201908624SA (en) | Aryl hydrocarbon receptor antagonists and uses thereof | |
| SG11201900545TA (en) | Pharmaceutical compounds | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof |